Skip to main content

Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery.

Publication ,  Journal Article
Park, C; Buckley, ED; Van Swearingen, AED; Giles, W; Herndon, JE; Kirkpatrick, JP; Anders, CK; Floyd, SR
Published in: Front Oncol
2022

BACKGROUND: There is a concern that HER2-directed systemic therapies, when administered concurrently with stereotactic radiosurgery (SRS), may increase the risk of radiation necrosis (RN). This study explores the impact of timing and type of systemic therapies on the development of RN in patients treated with SRS for HER2+ breast cancer brain metastasis (BCBrM). METHODS: This was a single-institution, retrospective study including patients >18 years of age with HER2+ BCBrM who received SRS between 2013 and 2018 and with at least 12-month post-SRS follow-up. Presence of RN was determined via imaging at one-year post-SRS, with confirmation by biopsy in some patients. Demographics, radiotherapy parameters, and timing ("during" defined as four weeks pre- to four weeks post-SRS) and type of systemic therapy (e.g., chemotherapy, HER2-directed) were evaluated. RESULTS: Among 46 patients with HER2+ BCBrM who received SRS, 28 (60.9%) developed RN and 18 (39.1%) did not based on imaging criteria. Of the 11 patients who underwent biopsy, 10/10 (100%) who were diagnosed with RN on imaging were confirmed to be RN positive on biopsy and 1/1 (100%) who was not diagnosed with RN was confirmed to be RN negative on biopsy. Age (mean 53.3 vs 50.4 years, respectively), radiotherapy parameters (including total dose, fractionation, CTV and size target volume, all p>0.05), and receipt of any type of systemic therapy during SRS (60.7% vs 55.6%, p=0.97) did not differ between patients who did or did not develop RN. However, there was a trend for patients who developed RN to have received more than one agent of HER2-directed therapy independent of SRS timing compared to those who did not develop RN (75.0% vs 44.4%, p=0.08). Moreover, a significantly higher proportion of those who developed RN received more than one agent of HER2-directed therapy during SRS treatment compared to those who did not develop RN (35.7% vs 5.6%, p=0.047). CONCLUSIONS: Patients with HER2 BCBrM who receive multiple HER2-directed therapies during SRS for BCBrM may be at higher risk of RN. Collectively, these data suggest that, in the eight-week window around SRS administration, if HER2-directed therapy is medically necessary, it is preferable that patients receive a single agent.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2022

Volume

12

Start / End Page

854364

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Park, C., Buckley, E. D., Van Swearingen, A. E. D., Giles, W., Herndon, J. E., Kirkpatrick, J. P., … Floyd, S. R. (2022). Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery. Front Oncol, 12, 854364. https://doi.org/10.3389/fonc.2022.854364
Park, Christine, Evan D. Buckley, Amanda E. D. Van Swearingen, Will Giles, James E. Herndon, John P. Kirkpatrick, Carey K. Anders, and Scott R. Floyd. “Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery.Front Oncol 12 (2022): 854364. https://doi.org/10.3389/fonc.2022.854364.
Park C, Buckley ED, Van Swearingen AED, Giles W, Herndon JE, Kirkpatrick JP, et al. Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery. Front Oncol. 2022;12:854364.
Park, Christine, et al. “Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery.Front Oncol, vol. 12, 2022, p. 854364. Pubmed, doi:10.3389/fonc.2022.854364.
Park C, Buckley ED, Van Swearingen AED, Giles W, Herndon JE, Kirkpatrick JP, Anders CK, Floyd SR. Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery. Front Oncol. 2022;12:854364.

Published In

Front Oncol

DOI

ISSN

2234-943X

Publication Date

2022

Volume

12

Start / End Page

854364

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis